Search

Displaying results 251 - 260 of 4584 in total
  1. Indication

    Osteoporosis caused by Glucocorticoid Treatment

    go.drugbank.com/conditions/DBCOND0129307
    Drugs: Alendronic acid · Denosumab · Nandrolone · Raloxifene · Teriparatide · Zoledronic acid
    Synonyms: Age-related osteoporosis without current pathological fracture
  2. Indication

    Crohn's Disease Relapse

    go.drugbank.com/conditions/DBCOND0123035
    Drugs: Mesalazine
    Synonyms: Crohn's disease, unspecified, without complications
  3. Indication

    Chronic Hepatitis B Infection

    go.drugbank.com/conditions/DBCOND0058876
    Drugs: Adefovir dipivoxil · Entecavir · Interferon alfa-2a · Interferon alfa-2b · Lamivudine · Peginterferon alfa-2a +4 more
    Synonyms: Chronic viral hepatitis B without delta-agent
  4. Indication

    Malignant Neoplasms

    go.drugbank.com/conditions/DBCOND0029679
    Drugs: Allopurinol · Dalteparin · Dexamethasone · Hydrocortisone succinate · Interferon alfa-2a · Lipegfilgrastim +5 more
    Synonyms: Malignant neoplasm without specification of site, [X]Malignant neoplasm without specification of site (disorder)
  5. Indication

    Crohn's Ileocolitis

    go.drugbank.com/conditions/DBCOND0073538
    Drugs: Mesalazine
    Synonyms: Crohn's disease, unspecified, without complications
  6. Drug

    Povidone-iodine

    go.drugbank.com/drugs/DB06812
    ApprovedInvestigational

    This unique complex was discovered in 1955 at the Industrial Toxicology Laboratories in Philadelphia by H. A. Shelanski and M. V. Shelanski.

    Products: Vida Mia Povidone Iodine
  7. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

  8. Drug

    Enoxaparin

    go.drugbank.com/drugs/DB01225
    ApprovedInvestigational

    [L31393] Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.

  9. Indication

    Gastro-esophageal Reflux Disease (GERD)

    go.drugbank.com/conditions/DBCOND0077290
    Drugs: Alginic acid · Aluminum hydroxide · Belladonna · Calcium carbonate · Cimetidine · Cinitapride +17 more
    Synonyms: Gastro-esophageal reflux disease without esophagitis, Oesophageal reflux (& [without mention of oesophagitis])
  10. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065] … [L56058,A275435] Navepegritide is a prodrug of active C-type natriuretic peptide (CNP) consisting of a CNP moiety transiently conjugated to two methoxy polyethylene glycol (mPEG) moieties via a proprietary